Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02866695 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

A Phase 4 study of Actinic Keratosis, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT02866695 is a Phase 4 study of Actinic Keratosis that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 188-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02866695, a Phase 4 study of Actinic Keratosis, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant recipients. The investigators have selected these two populations as the represent the spectrum of solid organ transplantation: kidney transplant recipients are the largest transplant population, but have lower levels of immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of skin cancer and actinic keratoses.

Conditions Studied

Interventions

  • DRUG ingenol mebutate gel 0.015%

Study Locations (1)

California

  • UCSF Dermatology - San Francisco

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-10-06
Est. Completion 2018-07-02
Phase Phase 4

What the Registry Record Tells You About NCT02866695

The ClinicalTrials.gov registry entry for NCT02866695 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (89% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 1 intervention - of which ingenol mebutate gel 0.015% is the first listed.

NCT02866695 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02866695 about?

NCT02866695 is a clinical study titled "Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients". This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant recipients. The investigators have selected these two populations as the represen...

What is the current status of trial NCT02866695?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2016-10-06. Estimated completion is 2018-07-02.

What conditions does trial NCT02866695 study?

This clinical trial studies the following conditions: Actinic Keratosis.

What interventions are being tested in trial NCT02866695?

The interventions under investigation include: ingenol mebutate gel 0.015% (DRUG).

Who is sponsoring clinical trial NCT02866695?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02866695 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.